OTP comments Q2 earnings report.
Over 3.77 million shares.
Pessimism rises some.
For drug launch in the United States.
He also becomes SB Chairman at Slovnaft.
Czech Republic, Romania, Serbia among potential targets.
Hungary's leading pharma company reacts.
Upside potential remains high, though.
For parent company Deutsche Telekom.
OTP decline in May has a lot to do with popularity.
For its incentive programme.
That is more than EUR 3.8 million.
Recommendations for Esmya approved by CHMP.
Fonte Viva was established in 2002.
To HUF 5,470 from HUF 5,695.